INVA-8001 is under clinical development by Invea Therapeutics and currently in Phase I for Atopic Dermatitis (Atopic Eczema). According to GlobalData, Phase I drugs for Atopic Dermatitis (Atopic Eczema) have an 86% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how INVA-8001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
INVA-8001 overview
INVA-8001 (ASB-17061) is under development for the treatment of prurigo nodularis (PN), chronic urticaria (CU). It is administered through oral route and acts by targeting chymase. The drug candidate is being developed based on AlphaMeld platform.
The drug candidate was under development for the treatment of atopic dermatitis (AD), indolent systemic mastocytosis (ISM), ulcerative colitis, mastocytosis, eosinophil associated gastrointestinal disorders such as eosinophilic gastritis, eosinophilic esophagitis primary sclerosing cholangitis and primary biliary cholangitis.
Invea Therapeutics overview
Invea Therapeutics (Invea) is a biotechnology company focuses on the discovery of therapeutics for gastrointestinal and hepatobiliary disorders. Invea is headquartered in Guilford, Connecticut,the US.
For a complete picture of INVA-8001’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
